Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series C | Alive

Total Raised


Last Raised

$7.97M | 4 yrs ago

About InnoTherapy

Provider of hemostatic devices based on bioadhesive technology. The company develops a technology to control wound closure products, such as a hemostatic pad, multi-layered hemostat, anti-adhesive sealant, powder sprayed hemostat for biopsy, etc. The technology is used for various of surgical settings from topical invasions to severe injuries.

InnoTherapy Headquarters Location

25, Seonyu-ro 13-gil, Yeongdeungpo-gu Suite 1209, ACE Hitech City 2

Seoul, 07282,

South Korea

82 2 6959 1338

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing InnoTherapy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InnoTherapy is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,578 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

InnoTherapy Patents

InnoTherapy has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Drug delivery devices, Polysaccharides, Polymers, Biomaterials


Application Date


Grant Date



Related Topics

Dosage forms, Drug delivery devices, Polysaccharides, Polymers, Biomaterials



Latest InnoTherapy News

Strict regulations block commercial launch of bloodless syringe in Korea2022.01.21 13:57

Jan 21, 2022

Strict regulations block commercial launch of bloodless syringe in Korea 2022.01.21 13:57:50 | 2022.01.21 13:58:19 Receiver An innovative bloodless syringe needle developed three years ago in South Korea is barred from going to market in the face of regulatory barriers despite its high demand for the prevention of secondary infections among healthcare professionals. Scientists criticize the country’s current regulations on the innovative medical device designation for fast-track marketing review are too strict to encourage innovations. Innotherapy, a Korean bio-inspired technology company, developed a needle coated with a hemostatic substance and filed for its designation as an innovative medical device to the Ministry of Food and Drug Safety last June. The application was referred to the Ministry of Health and Welfare, but the top health regulator said the bloodless needle does not meet the innovative medical device criteria, adding it is difficult to decide in terms of safety although its innovativeness is recognized. In response, Innotherapy said it is working on supplemental documents to beef up safety data and re-submit its application this year. The needle was first developed by KAIST scientist Lee Hae-shin and in recognition of his invention Lee received the scientist award of the month from the government in October 2018. The needle is coated with a hemostatic substance and an adhesive substance similar to what mussels use to cling to rocks against crashing waves. A patch-type product using the same substance was already approved for its commercial use with approval from the Ministry of Food and Drug Safety in 2015 and from the U.S. Food and Drug Administration in 2016. A bloodless syringe can protect healthcare professionals from secondary infections that are mediated by the patient`s blood, such as AIDS, Ebola, and hepatitis. This syringe can also be used for injection treatment for patients with weak hemostasis due to hemophilia or diabetes. It is difficult to understand that a patch product with the same substance has already been commercialized, but the application for this needle product is not accepted for safety reasons, Lee said. By Lee Sae-bom, Jung Hee-young and Minu Kim FRI

InnoTherapy Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

InnoTherapy Rank

  • Where is InnoTherapy's headquarters?

    InnoTherapy's headquarters is located at 25, Seonyu-ro 13-gil, Yeongdeungpo-gu, Seoul.

  • What is InnoTherapy's latest funding round?

    InnoTherapy's latest funding round is Series C.

  • How much did InnoTherapy raise?

    InnoTherapy raised a total of $16.47M.

  • Who are the investors of InnoTherapy?

    Investors of InnoTherapy include CKD Venture Capital, Stassets Investment, KCLAVIS Investment, Songhyun Investment, Korea Development Bank and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.